In a patient with non‑ST‑segment elevation myocardial infarction who is taking apixaban (Eliquis), should therapeutic heparin be initiated?

Should Heparin Be Started in NSTEMI Patients on Eliquis?

Yes, therapeutic anticoagulation with heparin should be initiated in NSTEMI patients taking apixaban (Eliquis), but you must wait at least 24 hours after the last dose of apixaban before starting heparin to minimize bleeding risk.

Rationale and Clinical Approach

The 2020 ESC Guidelines for acute coronary syndromes clearly recommend anticoagulation as a cornerstone of NSTEMI management 1. The guideline specifies unfractionated heparin (UFH) dosing of 70-100 U/kg IV bolus (or 50-70 U/kg if GP IIb/IIIa inhibitors are planned) followed by infusion until the invasive procedure 1. This recommendation applies regardless of prior anticoagulation status.

Key Timing Considerations

The Eliquis FDA label explicitly states that the pharmacodynamic effect persists for at least 24 hours after the last dose (approximately two drug half-lives) 2. This creates a critical decision point:

• If <24 hours since last apixaban dose: The anticoagulant effect is still present. Starting heparin immediately creates overlapping anticoagulation with significantly increased bleeding risk
• If ≥24 hours since last apixaban dose: Apixaban effect has substantially diminished, making heparin initiation safer

Practical Management Algorithm

1. Document time of last apixaban dose immediately

2. If urgent PCI is needed within 24 hours of last dose:

   • Proceed with PCI using reduced-dose or no additional anticoagulation
   • Consider checking anti-Xa levels if available (though FDA label notes monitoring is not useful for clinical decisions) 2
   • Accept residual apixaban anticoagulation as sufficient coverage
   • Be aware that elevated baseline anti-Xa levels from DOACs can confuse heparin monitoring 3

3. If PCI can be delayed >24 hours:

   • Wait the full 24 hours from last apixaban dose
   • Then initiate weight-based UFH per ESC guidelines: 70-100 U/kg bolus 1
   • Target aPTT 50-70 seconds per ACC/AHA recommendations 4, 5

4. Monitor closely for bleeding complications, particularly in high-risk patients (elderly, low body weight <60 kg, renal dysfunction with creatinine ≥1.5 mg/dL) 6

Important Caveats and Pitfalls

Laboratory interference: Research demonstrates that apixaban significantly elevates heparin anti-Xa assays, leading to falsely elevated readings that may cause clinicians to inappropriately delay or reduce heparin dosing 3. These levels typically normalize after 12 hours but can cause confusion in acute management.

Bleeding risk: The combination of apixaban and heparin substantially increases major bleeding risk. One study showed major bleeding rates of 4.6% with heparin plus GP IIb/IIIa inhibitors in NSTEMI 7. Adding residual apixaban effect would further amplify this risk.

No bridging needed: The Eliquis label specifically states that bridging anticoagulation during the 24-48 hours after stopping apixaban is "not generally required" 2. This applies to elective procedures but provides guidance that short gaps in anticoagulation are acceptable.

Reversal agents: If immediate PCI is required and bleeding occurs, prothrombin complex concentrate (PCC) or andexanet alfa may be considered for apixaban reversal, though the FDA label notes these have not been evaluated in clinical studies 2.

Special Populations

For patients with renal dysfunction (creatinine ≥1.5 mg/dL), both apixaban clearance is reduced and heparin dosing becomes more unpredictable, with markedly high aPTTs more likely 6. These patients require even more cautious overlap management and closer monitoring.

Elderly patients (≥80 years) and those with low body weight (<60 kg) are at higher risk for both excessive anticoagulation and bleeding complications 6. Consider the lower end of heparin dosing ranges in these populations.